Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.
To clarify whether serum levels of interleukin-11 (IL-11) could be a useful marker in patients with prostate cancer, serum IL-11 was determined in 73 and 23 men with prostate cancer and benign prostate hyperplasia (BPH), respectively, before treatment. There were no statistical differences of IL-11 levels between patients with prostate cancer and BPH. Patients with hormone-resistant prostate cancer had a significantly higher level of IL-11 than those with untreated cancer. Serum IL-11 levels may be a potential tumor marker for prostate cancer progression.
Furuya
Yuzo
Y
Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan. furuyayu@med.teikyo-u.ac.jp
Nishio
Remon
R
Junicho
Akira
A
Nagakawa
Osamu
O
Fuse
Hideki
H
D000368:Aged; D015415:Biomarkers / Q000097:blood; D006801:Humans; D017370:Interleukin-11 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*
D015415:Biomarkers; D017370:Interleukin-11